文献速递皮肤肿瘤

FDG-PET影像对转移性黑色素瘤免疫治疗复发的预测价值

Predictive value of FDG-PET imaging for relapse in metastatic melanoma patients treated with immunotherapy.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-07-01

结果显示CT为PR或SD但FDG-PET为CMR者均未复发,FDG-PET评估的残留FDG摄取(RFA)与复发显著相关(P=0.00231)。

要点

  • CT为PR而FDG-PET为CMR者均未复发,可视为完全缓解。
  • FDG-PET评估的RFA与复发显著相关(P=0.00231)。
  • FDG-PET有助于判断长期预后及是否停药。

核心结论

  • CT为PR且FDG-PET为CMR的大多数患者应按完全缓解对待。
  • FDG-PET影像可能对预测长期结局及决定是否停药起关键作用。

研究设计与样本

  • CT与FDG-PET扫描须在停药后最多2个月内完成。
  • CT采用RECIST 1.1标准,FDG-PET代谢反应分为进展性代谢病、稳定性代谢病、残留FDG摄取(RFA)和完全代谢反应(CMR)。
  • 主要结局为随访期间复发。

主要发现

  • 2例CT为SD而FDG-PET为CMR者均未复发。
  • 达到完全缓解的平均治疗持续时间为7个月(范围3-23)。
  • 单因素分析显示FDG-PET评估的RFA与复发显著相关(P=0.00231)。

关键数值与推荐

  • CT采用RECIST 1.1标准,包括进展性疾病(PD)、稳定疾病(SD)、部分缓解(PR)和完全缓解(CR)。
  • FDG-PET代谢反应分为进展性代谢病、稳定性代谢病、残留FDG摄取(RFA)和完全代谢反应(CMR)。
  • CT与FDG-PET扫描须在停药后最多2个月内完成。

临床怎么用

  • 对CT为PR或SD的转移性黑色素瘤患者,可结合FDG-PET评估代谢反应以识别可视为完全缓解者。
  • FDG-PET显示CMR者可能支持考虑停止抗PD1治疗。
  • FDG-PET显示RFA提示复发风险较高,需加强随访。

局限性

  • 单因素分析显示RFA与复发相关,未报告多因素分析。
  • CT与FDG-PET须在停药后2个月内完成,时间窗限制可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-PD1 immunotherapy has shown a sustainable clinical activity in patients with metastatic melanoma. However, strong predictive factors of the long-term response or risk of relapse remain to be identified. OBJECTIVES: To determine whether FDG-PET imaging could be superior to CT scan in distinguishing residual tumours versus the absence of tumour in patients with a partial response (PR) or stable disease (SD) and whether a complete metabolic response (CMR) was associated with better outcomes. METHODS: Retrospective study conducted in all patients with metastatic melanoma treated with anti-PD1 immunotherapy between October 2014 and October 2017 considered to be in complete remission. The primary outcome was the occurrence of a relapse during the follow-up. CT scan and FDG-PET scan had to be performed within a maximum of 2 months of treatment discontinuation. For CT imaging, the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 were used and included progressive disease (PD), SD, PR and complete response (CR). For FDG-PET imaging, the metabolic responses were classified as progressive metabolic disease, stable metabolic disease, residual FDG avidity (RFA) and CMR. RESULTS: Twenty-six patients were in complete remission after collegial decision. Two patients had a SD on CT scan and a CMR on FDG-PET scan, and none of them relapsed. Ten patients had a PR on CT scan and a CMR on FDG-PET scan, and none of them relapsed. The mean treatment duration to achieve a complete remission was 7 months (3-23). A univariate analysis showed that a RFA assessed on the FDG-PET scan was significantly associated with a relapse (P = 0.00231). CONCLUSIONS: Most patients with a PR on the CT scan and a CMR on the FDG-PET scan should be considered with a CR. Our study showed that FDG-PET imaging could play a crucial role in predicting the long-term outcome and help to decide whether treatment should be discontinued.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Mesnard C, Bodet-Milin C, Eugène T, et al. Predictive value of FDG-PET imaging for relapse in metastatic melanoma patients treated with immunotherapy. J Eur Acad Dermatol Venereol. 2020. PMID: 32219890. doi:10.1111/jdv.16358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。